Trial Profile
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacodynamics
- 27 Nov 2023 Planned End Date changed from 1 Nov 2019 to 1 Dec 2024.
- 27 Nov 2023 Planned primary completion date changed from 1 May 2019 to 1 Dec 2023.
- 07 Jun 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.